My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Pascal Soriot Biography and Net Worth

Executive Director and Chief Executive Officer of AstraZeneca

Pascal brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Pascal received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.

How old is Pascal Soriot?: Mr. Soriot is currently 65 years old. There are 3 older executives and no younger executives at AstraZeneca. Learn More on Pascal Soriot's age.
How do I contact Pascal Soriot?: The corporate mailing address for Mr. Soriot and other AstraZeneca executives is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. AstraZeneca can also be reached via phone at 442037495000 and via email at [email protected]. Learn More on Pascal Soriot's contact information.
Has Pascal Soriot been buying or selling shares of AstraZeneca?: Pascal Soriot has not been actively trading shares of AstraZeneca during the last quarter. Learn More on Pascal Soriot's trading history.
Who are AstraZeneca's active insiders?: AstraZeneca's insider roster includes Katarina Ageborg (EVP of Sustainability), Pam Cheng (EVP of Operations & Information Technology and Member of External Sustainability Advisory Board ), Marc Dunoyer (CEO of Alexion & Chief Strategy Officer ), Menelas Pangalos (EVP ), Aradhana Sarin (CFO & Exec. Director ), and Pascal Soriot (Executive Director and Chief Executive Officer ). Learn More on AstraZeneca's active insiders.

Pascal Soriot Insider Trading History at AstraZeneca

Pascal Soriot Buying and Selling Activity at AstraZeneca

AstraZeneca Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $63.20

$62.88

$63.93

50 Day Range

MA: $73.99

$63.20

$79.58

2 Week Range

Now: $63.20

$60.47

$87.68

Volume

7,047,699 shs

Average Volume

7,884,636 shs

Market Capitalization

$195.96 billion

P/E Ratio

30.24

Dividend Yield

1.54%

Beta

0.47